Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
peptide drug
|
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:alternativeName |
gptkb:Jusvinza
|
| gptkbp:approvedBy |
gptkb:Cuba_(emergency_use_for_COVID-19)
|
| gptkbp:clinicalTrialsIn |
gptkb:Cuba
|
| gptkbp:compatibleWith |
FDA (as of 2024)
|
| gptkbp:countryOfOrigin |
gptkb:Cuba
|
| gptkbp:derivedFrom |
gptkb:human_heat_shock_protein_60_(HSP60)
|
| gptkbp:developedBy |
gptkb:Center_for_Genetic_Engineering_and_Biotechnology_(CIGB),_Cuba
|
| gptkbp:effect |
reduces cytokine storm
reduces inflammation |
| https://www.w3.org/2000/01/rdf-schema#label |
CIGB-258
|
| gptkbp:mechanismOfAction |
immunomodulatory
|
| gptkbp:status |
investigational drug
|
| gptkbp:target |
immune system
|
| gptkbp:usedFor |
gptkb:COVID-19
treatment of inflammatory diseases |
| gptkbp:bfsParent |
gptkb:CIGBS
|
| gptkbp:bfsLayer |
6
|